Avalo Therapeutics Inc.
Organization details
- Legal name
- Avalo Therapeutics Inc.
- Former names
- Cerecor Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Wayne
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AVTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001534120
- EIN
- 45-0705648
Board of directors
-
Aaron Kantoff · DirectorSince 2024
-
Garry Arthur Neil · Director · Chief Executive OfficerSince 2023
-
Gilla Kaplan · DirectorSince 2023
-
Jonathan Goldman · DirectorSince 2024
-
June Sherie Almenoff · DirectorSince 2023
-
Kevin Robert Lind · DirectorSince 2025
-
Magnus Persson · DirectorSince 2023
- Since 2025
-
Mitchell Chan · DirectorSince 2023
- Since 2025
-
Ron M. Philip · DirectorSince 2026
-
Samantha Truex · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
100.0%
-
100.0%
-
100.0%
-
100.0%
Board connections
7 of this board's directors also sit on 15 other boards. 15 are in the same sector.
-
Celldex Therapeutics Inc. Same sectorvia Garry Arthur Neil and Rita Jain
-
Actinium Pharmaceuticals Inc. (Delaware) Same sectorvia June Sherie Almenoff
-
AnaptysBio Inc. Same sectorvia Rita Jain
-
Apnimed Inc. Same sectorvia Kevin Robert Lind
-
Biohaven Ltd. Same sectorvia Michael Thomas Heffernan
-
City Therapeutics Inc. Same sectorvia Ron M. Philip
-
Collegium Pharmaceutical Inc. Same sectorvia Michael Thomas Heffernan
-
First Tracks Biotherapeutics Inc. Same sectorvia Rita Jain
-
Harmony Biosciences Holdings Inc. Same sectorvia Ron M. Philip
-
SAB Biotherapeutics Inc. Same sectorvia Rita Jain
-
Tenax Therapeutics Inc. Same sectorvia June Sherie Almenoff
-
Trevi Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
-
Tyra Biosciences Inc. Same sectorvia Gilla Kaplan
-
Zura Bio Limited Same sectorvia Garry Arthur Neil
-
enGene Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $8,501,946
- 43 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 16, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Option exercise | +12,394 | $9.88 | $122,453 |
| Sep 16, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Open-market sale | −12,394 | $16.33 | $202,394 |
| Sep 10, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Option exercise | +10,185 | $8.04 | $81,887 |
| Sep 10, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Open-market sale | −10,185 | $17.62 | $179,460 |
| Aug 28, 2026 | Mittie Doyle Officer (Chief Medical Officer) | Option exercise | +679 | $8.04 | $5,459 |
| Aug 28, 2026 | Mittie Doyle Officer (Chief Medical Officer) | Open-market sale | −679 | $20.00 | $13,580 |
| Aug 18, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Option exercise | +31,031 | $9.88 | $306,586 |
| Aug 18, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Open-market sale | −31,031 | $20.05 | $622,172 |
| Aug 17, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Option exercise | +37,945 | $9.88 | $374,897 |
| Aug 17, 2026 | Mittie Doyle Officer (Chief Medical Officer) | Option exercise | +1,000 | $12.65 | $12,650 |
| Aug 17, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Option exercise | +2,876 | $9.88 | $28,415 |
| Aug 17, 2026 | Mittie Doyle Officer (Chief Medical Officer) | Open-market sale | −1,000 | $20.00 | $20,000 |
| Aug 17, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Open-market sale | −37,945 | $19.85 | $753,208 |
| Aug 17, 2026 | Sullivan Christopher Ryan Officer (Chief Financial Officer) | Open-market sale | −3,749 | $19.94 | $74,755 |
| Aug 11, 2026 | Riley Jennifer Officer (Chief Strategy Officer) | Open-market sale | −2,655 | $19.59 | $52,011 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Avalo Therapeutics Inc.
Who is the CEO of Avalo Therapeutics Inc.?
Garry Arthur Neil is Avalo Therapeutics Inc.'s CEO and Chairman of the Board.
How many directors are on Avalo Therapeutics Inc.'s board?
Avalo Therapeutics Inc.'s board has 12 directors: Aaron Kantoff, Garry Arthur Neil, Gilla Kaplan, Jonathan Goldman, June Sherie Almenoff, Kevin Robert Lind, Magnus Persson, Michael Thomas Heffernan, Mitchell Chan, Rita Jain and 2 others.
Are Avalo Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Avalo Therapeutics Inc. insiders made no open-market purchases and sold $8.5 million of shares in 43 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="avalo-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.